Robert Herring

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

Nezam H. Afdhal, K. Rajender Reddy, David R. Nelson et al. · New England Journal of Medicine · 2014 · 1.3K citations

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Interim Analysis, Metabolic Associated Steatohepatitis, Hepatology +7

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

Kris V. Kowdley, Stuart C. Gordon, K. Rajender Reddy et al. · New England Journal of Medicine · 2014 · 1.1K citations · Full text

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 438 citations

Fibrosis, Hepatology, Liver Physiology +9

Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial

Keyur Patel, Stephen A. Harrison, Magdy Elkhashab et al. · Hepatology · 2020 · 311 citations